Review



mouse rankl  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    R&D Systems mouse rankl
    Dual inhibition of TGF-β and sclerostin increases bone mass in a hindlimb unloading model. a Experimental timeline of hindlimb unloading using C57B1/6 J mice and treatment with TGFβ-Ab, Scl-Ab, or both. Mice euthanized at week 12. b Representative μCT images of femoral diaphysis. c Representative confocal images of trabecular bone showing calcein (green), alizarin (red) signals, and DAPI (blue). Scale bar = 100 μm. d Representative images of TRAP-stained femur sections; violet = TRAP-positive, green = counterstain. Scale bar = 200 μm. e – h Bar plot of trabecular bone volume/total volume (Tra. BV/TV, e ), trabecular thickness (Tb. Th, f ), trabecular separation (Tb. Sp, g ), and trabecular number (Tb. N, h ) from μCT. Data = mean ± standard deviation. i , j Bar plot of mineral apposition rate (Tra. MAR, i ) and trabecular bone formation rate per bone surface (Tra. BFR/BS, j ) from labeling images. Data = mean ± standard deviation k Box plot of TRAP+ osteoclasts per bone surface (OC.N/BS), measured through ImageJ from TRAP-stained slides. l – n Box plot of serum P1NP ( l ) and TRAP ( m ) levels, <t>and</t> <t>RANKL/OPG</t> ratio ( n ). Group sizes: Control ( n = 5), Un_con ( n = 5), Scl-Ab ( n = 6), TGFβ-Ab ( n = 6), and Scl-Ab+TGFβ-Ab ( n = 7). Each point represents an individual mouse. ANOVA was used for statistics; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.000 1; ns not significant
    Mouse Rankl, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 111 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rankl+elisa+kit/Mouse+TRANCE%2FRANK+L%2FTNFSF11+Quantikine+ELISA+Kit/pmc13046724-292-48-51
    Average 95 stars, based on 111 article reviews
    mouse rankl - by Bioz Stars, 2026-09
    95/100 stars

    Images

    1) Product Images from "Spatially resolved osteoblast-traced transcriptomics uncovers TGF-β as a combination target with sclerostin in osteoporosis"

    Article Title: Spatially resolved osteoblast-traced transcriptomics uncovers TGF-β as a combination target with sclerostin in osteoporosis

    Journal: Bone Research

    doi: 10.1038/s41413-026-00521-9

    Dual inhibition of TGF-β and sclerostin increases bone mass in a hindlimb unloading model. a Experimental timeline of hindlimb unloading using C57B1/6 J mice and treatment with TGFβ-Ab, Scl-Ab, or both. Mice euthanized at week 12. b Representative μCT images of femoral diaphysis. c Representative confocal images of trabecular bone showing calcein (green), alizarin (red) signals, and DAPI (blue). Scale bar = 100 μm. d Representative images of TRAP-stained femur sections; violet = TRAP-positive, green = counterstain. Scale bar = 200 μm. e – h Bar plot of trabecular bone volume/total volume (Tra. BV/TV, e ), trabecular thickness (Tb. Th, f ), trabecular separation (Tb. Sp, g ), and trabecular number (Tb. N, h ) from μCT. Data = mean ± standard deviation. i , j Bar plot of mineral apposition rate (Tra. MAR, i ) and trabecular bone formation rate per bone surface (Tra. BFR/BS, j ) from labeling images. Data = mean ± standard deviation k Box plot of TRAP+ osteoclasts per bone surface (OC.N/BS), measured through ImageJ from TRAP-stained slides. l – n Box plot of serum P1NP ( l ) and TRAP ( m ) levels, and RANKL/OPG ratio ( n ). Group sizes: Control ( n = 5), Un_con ( n = 5), Scl-Ab ( n = 6), TGFβ-Ab ( n = 6), and Scl-Ab+TGFβ-Ab ( n = 7). Each point represents an individual mouse. ANOVA was used for statistics; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.000 1; ns not significant
    Figure Legend Snippet: Dual inhibition of TGF-β and sclerostin increases bone mass in a hindlimb unloading model. a Experimental timeline of hindlimb unloading using C57B1/6 J mice and treatment with TGFβ-Ab, Scl-Ab, or both. Mice euthanized at week 12. b Representative μCT images of femoral diaphysis. c Representative confocal images of trabecular bone showing calcein (green), alizarin (red) signals, and DAPI (blue). Scale bar = 100 μm. d Representative images of TRAP-stained femur sections; violet = TRAP-positive, green = counterstain. Scale bar = 200 μm. e – h Bar plot of trabecular bone volume/total volume (Tra. BV/TV, e ), trabecular thickness (Tb. Th, f ), trabecular separation (Tb. Sp, g ), and trabecular number (Tb. N, h ) from μCT. Data = mean ± standard deviation. i , j Bar plot of mineral apposition rate (Tra. MAR, i ) and trabecular bone formation rate per bone surface (Tra. BFR/BS, j ) from labeling images. Data = mean ± standard deviation k Box plot of TRAP+ osteoclasts per bone surface (OC.N/BS), measured through ImageJ from TRAP-stained slides. l – n Box plot of serum P1NP ( l ) and TRAP ( m ) levels, and RANKL/OPG ratio ( n ). Group sizes: Control ( n = 5), Un_con ( n = 5), Scl-Ab ( n = 6), TGFβ-Ab ( n = 6), and Scl-Ab+TGFβ-Ab ( n = 7). Each point represents an individual mouse. ANOVA was used for statistics; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.000 1; ns not significant

    Techniques Used: Inhibition, Staining, Standard Deviation, Labeling, Control

    Related Articles

    other:

    Article Title: Monomethylfumarate Protects against Ovariectomy-related Changes in Body Composition
    Article Snippet: RANKL and OPG ELISA kits were purchased from R&D Systems (Minneapolis, MN) and the PYD ELISA kit from Quidel Corp. (San Diego, CA).

    Article Title: α-Tocopheryl Succinate Inhibits Osteolytic Bone Metastasis of Breast Cancer by Suppressing Migration of Cancer Cells and Receptor Activator of Nuclear Factor-κB Ligand Expression of Osteoblasts
    Article Snippet: The protein levels of mouse RANKL and mouse OPG in samples collected as indicated above were measured by using the corresponding ELISA kits (R & D Systems) according to the manufacturer's instructions.


    Enzyme-linked Immunosorbent Assay:

    Article Title: Loss of phosphatidylinositol-4-phosphate 5-kinase type-1 gamma (Pip5k1c) in mesenchymal stem cells leads to osteopenia by impairing bone remodeling
    Article Snippet: .. Serum P1NP, CTX-1, Rankl, and Opg were measured by using P1NP ELISA kit (Immunodiagnostic Systems Limited, cat# AC-33F1), CTX-1 ELISA kit (Immunodiagnostic Systems Limited, cat# AC-06F1), Rankl ELISA kit (R&D, cat# MTR00), and Opg ELISA kit (R&D, cat# MOP00), respectively, according to the manufacturers' instructions. ..

    Article Title: Receptor agonist of NFκB signaling ligand directs lung epithelial cell expansion through RANK signaling.
    Article Snippet: Habibie Habibie , Jelmer R. Vlasma , Kurnia S.S. Putri ,Shanshan 3 Song, Marina H. de Jager, Arjen Petersen, Carian E Boorsma, Robbert H 4 Cool, Wim Quax, Martijn C Nawijn, Wim Timens, Janette K. Burgess, 5 Corry-Anke Brandsma , Barbro N Melgert 6 1.. University of Groningen, University Medical Center Groningen, GRIAC Research 7 Institute, Groningen, The Netherlands.. 8 2.

    Article Title: Receptor agonist of NFκB signaling ligand directs lung epithelial cell expansion through RANK signaling
    Article Snippet: .. Protein purity was checked by SDS-PAGE and RANKL concentrations were measured with a Coomassie Bradford protein assay kit (#23200, Thermo Fisher) using bovine serum albumin as reference and with a RANKL ELISA kit according to the manufacturer’s instructions (#DY626, R&D Systems, Minneapolis, Minnesota, USA). ..

    Article Title: Tetrahydroxystilbene Glucoside Regulates Proliferation, Differentiation, and OPG/RANKL/M-CSF Expression in MC3T3-E1 Cells via the PI3K/Akt Pathway
    Article Snippet: GAPDH, β-actin, and β-tublin antibodies were purchased from Abclonal (Wuhan, China). .. OPG and RANKL ELISA kits were purchased from R&D Systems (Minneapolis, MN, USA). ..

    Article Title: Alterations in osteocyte mediated osteoclastogenesis during estrogen deficiency and under ROCK-II inhibition: An in vitro study using a novel postmenopausal multicellular niche model.
    Article Snippet: .. We are thankful to Professor Lidan You and her research group at University of Toronto for sharing their RANKL ELISA kit (R&D Systems – DY462) as used in this study. ..

    SDS Page:

    Article Title: Receptor agonist of NFκB signaling ligand directs lung epithelial cell expansion through RANK signaling.
    Article Snippet: Habibie Habibie , Jelmer R. Vlasma , Kurnia S.S. Putri ,Shanshan 3 Song, Marina H. de Jager, Arjen Petersen, Carian E Boorsma, Robbert H 4 Cool, Wim Quax, Martijn C Nawijn, Wim Timens, Janette K. Burgess, 5 Corry-Anke Brandsma , Barbro N Melgert 6 1.. University of Groningen, University Medical Center Groningen, GRIAC Research 7 Institute, Groningen, The Netherlands.. 8 2.

    Article Title: Receptor agonist of NFκB signaling ligand directs lung epithelial cell expansion through RANK signaling
    Article Snippet: .. Protein purity was checked by SDS-PAGE and RANKL concentrations were measured with a Coomassie Bradford protein assay kit (#23200, Thermo Fisher) using bovine serum albumin as reference and with a RANKL ELISA kit according to the manufacturer’s instructions (#DY626, R&D Systems, Minneapolis, Minnesota, USA). ..

    Bradford Protein Assay:

    Article Title: Receptor agonist of NFκB signaling ligand directs lung epithelial cell expansion through RANK signaling.
    Article Snippet: Habibie Habibie , Jelmer R. Vlasma , Kurnia S.S. Putri ,Shanshan 3 Song, Marina H. de Jager, Arjen Petersen, Carian E Boorsma, Robbert H 4 Cool, Wim Quax, Martijn C Nawijn, Wim Timens, Janette K. Burgess, 5 Corry-Anke Brandsma , Barbro N Melgert 6 1.. University of Groningen, University Medical Center Groningen, GRIAC Research 7 Institute, Groningen, The Netherlands.. 8 2.

    Article Title: Receptor agonist of NFκB signaling ligand directs lung epithelial cell expansion through RANK signaling
    Article Snippet: .. Protein purity was checked by SDS-PAGE and RANKL concentrations were measured with a Coomassie Bradford protein assay kit (#23200, Thermo Fisher) using bovine serum albumin as reference and with a RANKL ELISA kit according to the manufacturer’s instructions (#DY626, R&D Systems, Minneapolis, Minnesota, USA). ..



    Similar Products

    92
    Multi Sciences (Lianke) Biotech Co Ltd human tnfsf11 elisa kit multisciences cat
    Human Tnfsf11 Elisa Kit Multisciences Cat, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rankl+elisa+kit/Human+TRANCE%2FTNFSF11%2FRANKL+ELISA+Kit/pm40930100-210-65-69
    Average 92 stars, based on 1 article reviews
    human tnfsf11 elisa kit multisciences cat - by Bioz Stars, 2026-09
    92/100 stars
      Buy from Supplier

    95
    R&D Systems mouse rankl
    Dual inhibition of TGF-β and sclerostin increases bone mass in a hindlimb unloading model. a Experimental timeline of hindlimb unloading using C57B1/6 J mice and treatment with TGFβ-Ab, Scl-Ab, or both. Mice euthanized at week 12. b Representative μCT images of femoral diaphysis. c Representative confocal images of trabecular bone showing calcein (green), alizarin (red) signals, and DAPI (blue). Scale bar = 100 μm. d Representative images of TRAP-stained femur sections; violet = TRAP-positive, green = counterstain. Scale bar = 200 μm. e – h Bar plot of trabecular bone volume/total volume (Tra. BV/TV, e ), trabecular thickness (Tb. Th, f ), trabecular separation (Tb. Sp, g ), and trabecular number (Tb. N, h ) from μCT. Data = mean ± standard deviation. i , j Bar plot of mineral apposition rate (Tra. MAR, i ) and trabecular bone formation rate per bone surface (Tra. BFR/BS, j ) from labeling images. Data = mean ± standard deviation k Box plot of TRAP+ osteoclasts per bone surface (OC.N/BS), measured through ImageJ from TRAP-stained slides. l – n Box plot of serum P1NP ( l ) and TRAP ( m ) levels, <t>and</t> <t>RANKL/OPG</t> ratio ( n ). Group sizes: Control ( n = 5), Un_con ( n = 5), Scl-Ab ( n = 6), TGFβ-Ab ( n = 6), and Scl-Ab+TGFβ-Ab ( n = 7). Each point represents an individual mouse. ANOVA was used for statistics; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.000 1; ns not significant
    Mouse Rankl, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rankl+elisa+kit/Mouse+TRANCE%2FRANK+L%2FTNFSF11+Quantikine+ELISA+Kit/pmc13046724-292-48-51
    Average 95 stars, based on 1 article reviews
    mouse rankl - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    94
    R&D Systems rankl elisa kit
    Dual inhibition of TGF-β and sclerostin increases bone mass in a hindlimb unloading model. a Experimental timeline of hindlimb unloading using C57B1/6 J mice and treatment with TGFβ-Ab, Scl-Ab, or both. Mice euthanized at week 12. b Representative μCT images of femoral diaphysis. c Representative confocal images of trabecular bone showing calcein (green), alizarin (red) signals, and DAPI (blue). Scale bar = 100 μm. d Representative images of TRAP-stained femur sections; violet = TRAP-positive, green = counterstain. Scale bar = 200 μm. e – h Bar plot of trabecular bone volume/total volume (Tra. BV/TV, e ), trabecular thickness (Tb. Th, f ), trabecular separation (Tb. Sp, g ), and trabecular number (Tb. N, h ) from μCT. Data = mean ± standard deviation. i , j Bar plot of mineral apposition rate (Tra. MAR, i ) and trabecular bone formation rate per bone surface (Tra. BFR/BS, j ) from labeling images. Data = mean ± standard deviation k Box plot of TRAP+ osteoclasts per bone surface (OC.N/BS), measured through ImageJ from TRAP-stained slides. l – n Box plot of serum P1NP ( l ) and TRAP ( m ) levels, <t>and</t> <t>RANKL/OPG</t> ratio ( n ). Group sizes: Control ( n = 5), Un_con ( n = 5), Scl-Ab ( n = 6), TGFβ-Ab ( n = 6), and Scl-Ab+TGFβ-Ab ( n = 7). Each point represents an individual mouse. ANOVA was used for statistics; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.000 1; ns not significant
    Rankl Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rankl+elisa+kit/Human+TRANCE%2FRANK+L%2FTNFSF11+DuoSet+ELISA/pm41605458-44-33-43
    Average 94 stars, based on 1 article reviews
    rankl elisa kit - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    Proteintech opg
    COL-I, OCN, <t>OPG</t> and RANKL protein expression levels in each group after 8 weeks of intervention. (A) COL-I, OCN, OPG and RANKL protein expression level of each treatment group. Average optical density of (B) COL-I, (C) OCN, (D) OPG and (E) RANKL in each group. *P<0.05 vs. Ctrl group; # P<0.05 vs. T2DM model group. COL-I, type I collagen; <t>OCN,</t> <t>osteocalcin;</t> OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand; Ctrl, control; T2DM, type 2 diabetes mellitus; ZnC, zinc carnosine; AOD, average optical density value.
    Opg, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rankl+elisa+kit/Mouse+TNFSF11%2FRANKL+ELISA+Kit/pmc12587476-121-31-36
    Average 94 stars, based on 1 article reviews
    opg - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    95
    R&D Systems mouse rankl immunoassay kit
    Schematic depicting experiments utilizing the Sox9 CreERT ;Gnas R201H mouse model of FD. (A) Dams from crosses able to generate Sox9 CreERT ;Gnas (R201H)fl/+ ;Rosa26 LSL-tdTomato offspring were treated with a low dose of tamoxifen (40 mg/kg) at P6. Tamoxifen is then delivered to the pups via lactation, which allows expression of both mutant Gnas R201H and tdTomato as a lineage tracer in the subset of osteoprogenitor cells expressing Sox9 at P6. Resultant Gnas R201H ;R26 Tom mutant mice were then injected with either IgG2a or <t>anti-RANKL</t> antibody weekly until either P21 or P42 (3 or 6 wk of age). Femurs were collected for analysis. (B) Dams from crosses able to generate Sox9 CreERT ;Gnas (R201H)fl/+ ;Rosa26 LSL-tdTomato mice with either Rankl fl/fl or Rankl fl/+ or Rankl +/+ were genotyped to determine RANKL deletion. Pups were ear notched and genotyped at P5, the dam was treated with a low dose of tamoxifen (40 mg/kg) at P6 to deliver tamoxifen to the pups via lactation. Femurs were collected for analysis at either P21 or P42 (3 or 6 wk of age).
    Mouse Rankl Immunoassay Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rankl+elisa+kit/Mouse+TRANCE%2FRANK+L%2FTNFSF11+Quantikine+ELISA+Kit/pmc12478024-96-12-17
    Average 95 stars, based on 1 article reviews
    mouse rankl immunoassay kit - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    93
    Krishgen Biosystems elisa kits
    Schematic depicting experiments utilizing the Sox9 CreERT ;Gnas R201H mouse model of FD. (A) Dams from crosses able to generate Sox9 CreERT ;Gnas (R201H)fl/+ ;Rosa26 LSL-tdTomato offspring were treated with a low dose of tamoxifen (40 mg/kg) at P6. Tamoxifen is then delivered to the pups via lactation, which allows expression of both mutant Gnas R201H and tdTomato as a lineage tracer in the subset of osteoprogenitor cells expressing Sox9 at P6. Resultant Gnas R201H ;R26 Tom mutant mice were then injected with either IgG2a or <t>anti-RANKL</t> antibody weekly until either P21 or P42 (3 or 6 wk of age). Femurs were collected for analysis. (B) Dams from crosses able to generate Sox9 CreERT ;Gnas (R201H)fl/+ ;Rosa26 LSL-tdTomato mice with either Rankl fl/fl or Rankl fl/+ or Rankl +/+ were genotyped to determine RANKL deletion. Pups were ear notched and genotyped at P5, the dam was treated with a low dose of tamoxifen (40 mg/kg) at P6 to deliver tamoxifen to the pups via lactation. Femurs were collected for analysis at either P21 or P42 (3 or 6 wk of age).
    Elisa Kits, supplied by Krishgen Biosystems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rankl+elisa+kit/Rat+Receptor+activator+of+nuclear+Factor+kappa+B+ligand%2C+RANKL+GENLISA+ELISA/pm40842183-172-1-25
    Average 93 stars, based on 1 article reviews
    elisa kits - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    95
    R&D Systems mouse trance rankl tnfsf11 quantikine elisa kit
    Schematic depicting experiments utilizing the Sox9 CreERT ;Gnas R201H mouse model of FD. (A) Dams from crosses able to generate Sox9 CreERT ;Gnas (R201H)fl/+ ;Rosa26 LSL-tdTomato offspring were treated with a low dose of tamoxifen (40 mg/kg) at P6. Tamoxifen is then delivered to the pups via lactation, which allows expression of both mutant Gnas R201H and tdTomato as a lineage tracer in the subset of osteoprogenitor cells expressing Sox9 at P6. Resultant Gnas R201H ;R26 Tom mutant mice were then injected with either IgG2a or <t>anti-RANKL</t> antibody weekly until either P21 or P42 (3 or 6 wk of age). Femurs were collected for analysis. (B) Dams from crosses able to generate Sox9 CreERT ;Gnas (R201H)fl/+ ;Rosa26 LSL-tdTomato mice with either Rankl fl/fl or Rankl fl/+ or Rankl +/+ were genotyped to determine RANKL deletion. Pups were ear notched and genotyped at P5, the dam was treated with a low dose of tamoxifen (40 mg/kg) at P6 to deliver tamoxifen to the pups via lactation. Femurs were collected for analysis at either P21 or P42 (3 or 6 wk of age).
    Mouse Trance Rankl Tnfsf11 Quantikine Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rankl+elisa+kit/Mouse+TRANCE%2FRANK+L%2FTNFSF11+Quantikine+ELISA+Kit/pmc12513485-188-47-52
    Average 95 stars, based on 1 article reviews
    mouse trance rankl tnfsf11 quantikine elisa kit - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    95
    R&D Systems mn rankl mouse rank l tnfsf11 quantikine elisa kit
    Schematic depicting experiments utilizing the Sox9 CreERT ;Gnas R201H mouse model of FD. (A) Dams from crosses able to generate Sox9 CreERT ;Gnas (R201H)fl/+ ;Rosa26 LSL-tdTomato offspring were treated with a low dose of tamoxifen (40 mg/kg) at P6. Tamoxifen is then delivered to the pups via lactation, which allows expression of both mutant Gnas R201H and tdTomato as a lineage tracer in the subset of osteoprogenitor cells expressing Sox9 at P6. Resultant Gnas R201H ;R26 Tom mutant mice were then injected with either IgG2a or <t>anti-RANKL</t> antibody weekly until either P21 or P42 (3 or 6 wk of age). Femurs were collected for analysis. (B) Dams from crosses able to generate Sox9 CreERT ;Gnas (R201H)fl/+ ;Rosa26 LSL-tdTomato mice with either Rankl fl/fl or Rankl fl/+ or Rankl +/+ were genotyped to determine RANKL deletion. Pups were ear notched and genotyped at P5, the dam was treated with a low dose of tamoxifen (40 mg/kg) at P6 to deliver tamoxifen to the pups via lactation. Femurs were collected for analysis at either P21 or P42 (3 or 6 wk of age).
    Mn Rankl Mouse Rank L Tnfsf11 Quantikine Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rankl+elisa+kit/Mouse+TRANCE%2FRANK+L%2FTNFSF11+Quantikine+ELISA+Kit/pmc12513485__jciinsight-10-192981-s102-92-50-61
    Average 95 stars, based on 1 article reviews
    mn rankl mouse rank l tnfsf11 quantikine elisa kit - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    Image Search Results


    Dual inhibition of TGF-β and sclerostin increases bone mass in a hindlimb unloading model. a Experimental timeline of hindlimb unloading using C57B1/6 J mice and treatment with TGFβ-Ab, Scl-Ab, or both. Mice euthanized at week 12. b Representative μCT images of femoral diaphysis. c Representative confocal images of trabecular bone showing calcein (green), alizarin (red) signals, and DAPI (blue). Scale bar = 100 μm. d Representative images of TRAP-stained femur sections; violet = TRAP-positive, green = counterstain. Scale bar = 200 μm. e – h Bar plot of trabecular bone volume/total volume (Tra. BV/TV, e ), trabecular thickness (Tb. Th, f ), trabecular separation (Tb. Sp, g ), and trabecular number (Tb. N, h ) from μCT. Data = mean ± standard deviation. i , j Bar plot of mineral apposition rate (Tra. MAR, i ) and trabecular bone formation rate per bone surface (Tra. BFR/BS, j ) from labeling images. Data = mean ± standard deviation k Box plot of TRAP+ osteoclasts per bone surface (OC.N/BS), measured through ImageJ from TRAP-stained slides. l – n Box plot of serum P1NP ( l ) and TRAP ( m ) levels, and RANKL/OPG ratio ( n ). Group sizes: Control ( n = 5), Un_con ( n = 5), Scl-Ab ( n = 6), TGFβ-Ab ( n = 6), and Scl-Ab+TGFβ-Ab ( n = 7). Each point represents an individual mouse. ANOVA was used for statistics; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.000 1; ns not significant

    Journal: Bone Research

    Article Title: Spatially resolved osteoblast-traced transcriptomics uncovers TGF-β as a combination target with sclerostin in osteoporosis

    doi: 10.1038/s41413-026-00521-9

    Figure Lengend Snippet: Dual inhibition of TGF-β and sclerostin increases bone mass in a hindlimb unloading model. a Experimental timeline of hindlimb unloading using C57B1/6 J mice and treatment with TGFβ-Ab, Scl-Ab, or both. Mice euthanized at week 12. b Representative μCT images of femoral diaphysis. c Representative confocal images of trabecular bone showing calcein (green), alizarin (red) signals, and DAPI (blue). Scale bar = 100 μm. d Representative images of TRAP-stained femur sections; violet = TRAP-positive, green = counterstain. Scale bar = 200 μm. e – h Bar plot of trabecular bone volume/total volume (Tra. BV/TV, e ), trabecular thickness (Tb. Th, f ), trabecular separation (Tb. Sp, g ), and trabecular number (Tb. N, h ) from μCT. Data = mean ± standard deviation. i , j Bar plot of mineral apposition rate (Tra. MAR, i ) and trabecular bone formation rate per bone surface (Tra. BFR/BS, j ) from labeling images. Data = mean ± standard deviation k Box plot of TRAP+ osteoclasts per bone surface (OC.N/BS), measured through ImageJ from TRAP-stained slides. l – n Box plot of serum P1NP ( l ) and TRAP ( m ) levels, and RANKL/OPG ratio ( n ). Group sizes: Control ( n = 5), Un_con ( n = 5), Scl-Ab ( n = 6), TGFβ-Ab ( n = 6), and Scl-Ab+TGFβ-Ab ( n = 7). Each point represents an individual mouse. ANOVA was used for statistics; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.000 1; ns not significant

    Article Snippet: Serum levels of P1NP, CTx1, TRAcP, OPG, RANKL, and TGF-β1 were measured via an enzyme-linked immunosorbent assay (ELISA) performed using ELISA kit for mouse P1NP (AC-33F1, Immunodiagnostic Systems, UK), mouse CTx1 (AC-06F1, Immunodiagnostic Systems, UK), mouse TRAcP 5b (SB-TR103, Immunodiagnostic Systems, UK), mouse OPG (MOP00, R&D systems, USA), mouse RANKL (MTR00, R&D systems, USA), and mouse TGF-β1 (DY1679-05 and DY007B, R&D systems, USA) according to the manufacturer’s instruction.

    Techniques: Inhibition, Staining, Standard Deviation, Labeling, Control

    COL-I, OCN, OPG and RANKL protein expression levels in each group after 8 weeks of intervention. (A) COL-I, OCN, OPG and RANKL protein expression level of each treatment group. Average optical density of (B) COL-I, (C) OCN, (D) OPG and (E) RANKL in each group. *P<0.05 vs. Ctrl group; # P<0.05 vs. T2DM model group. COL-I, type I collagen; OCN, osteocalcin; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand; Ctrl, control; T2DM, type 2 diabetes mellitus; ZnC, zinc carnosine; AOD, average optical density value.

    Journal: Molecular Medicine Reports

    Article Title: Effects of zinc carnosine on bone loss in mice with diabetic osteoporosis

    doi: 10.3892/mmr.2025.13723

    Figure Lengend Snippet: COL-I, OCN, OPG and RANKL protein expression levels in each group after 8 weeks of intervention. (A) COL-I, OCN, OPG and RANKL protein expression level of each treatment group. Average optical density of (B) COL-I, (C) OCN, (D) OPG and (E) RANKL in each group. *P<0.05 vs. Ctrl group; # P<0.05 vs. T2DM model group. COL-I, type I collagen; OCN, osteocalcin; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand; Ctrl, control; T2DM, type 2 diabetes mellitus; ZnC, zinc carnosine; AOD, average optical density value.

    Article Snippet: The primary antibodies used and their dilution ratios are as follows: Type I collagen (COL-I; 1:200; cat. no. AF7001; Affinity Biosciences), osteocalcin (OCN, 1:200; cat. no. 16157-1-AP; Proteintech Group, Inc.) and OPG (1:200; cat. no 31766-1-AP; Proteintech Group, Inc.).

    Techniques: Expressing, Control

    mRNA expression levels of bone metabolism-related factors. *P<0.05 and ***P<0.01 vs. Ctrl group; ## P<0.01 vs. T2DM model group. (A) Ctrl, control; (B) T2DM, type 2 diabetes mellitus; (C) ZnC, zinc carnosine. OCN, osteocalcin; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand.

    Journal: Molecular Medicine Reports

    Article Title: Effects of zinc carnosine on bone loss in mice with diabetic osteoporosis

    doi: 10.3892/mmr.2025.13723

    Figure Lengend Snippet: mRNA expression levels of bone metabolism-related factors. *P<0.05 and ***P<0.01 vs. Ctrl group; ## P<0.01 vs. T2DM model group. (A) Ctrl, control; (B) T2DM, type 2 diabetes mellitus; (C) ZnC, zinc carnosine. OCN, osteocalcin; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand.

    Article Snippet: The primary antibodies used and their dilution ratios are as follows: Type I collagen (COL-I; 1:200; cat. no. AF7001; Affinity Biosciences), osteocalcin (OCN, 1:200; cat. no. 16157-1-AP; Proteintech Group, Inc.) and OPG (1:200; cat. no 31766-1-AP; Proteintech Group, Inc.).

    Techniques: Expressing, Control

    Schematic depicting experiments utilizing the Sox9 CreERT ;Gnas R201H mouse model of FD. (A) Dams from crosses able to generate Sox9 CreERT ;Gnas (R201H)fl/+ ;Rosa26 LSL-tdTomato offspring were treated with a low dose of tamoxifen (40 mg/kg) at P6. Tamoxifen is then delivered to the pups via lactation, which allows expression of both mutant Gnas R201H and tdTomato as a lineage tracer in the subset of osteoprogenitor cells expressing Sox9 at P6. Resultant Gnas R201H ;R26 Tom mutant mice were then injected with either IgG2a or anti-RANKL antibody weekly until either P21 or P42 (3 or 6 wk of age). Femurs were collected for analysis. (B) Dams from crosses able to generate Sox9 CreERT ;Gnas (R201H)fl/+ ;Rosa26 LSL-tdTomato mice with either Rankl fl/fl or Rankl fl/+ or Rankl +/+ were genotyped to determine RANKL deletion. Pups were ear notched and genotyped at P5, the dam was treated with a low dose of tamoxifen (40 mg/kg) at P6 to deliver tamoxifen to the pups via lactation. Femurs were collected for analysis at either P21 or P42 (3 or 6 wk of age).

    Journal: JBMR Plus

    Article Title: Neutralization of Receptor activator of nuclear factor-κB ligand reduces fibrosis and promotes osteoblast differentiation in a mouse model of fibrous dysplasia driven by somatic expression of Gnas R201H

    doi: 10.1093/jbmrpl/ziaf145

    Figure Lengend Snippet: Schematic depicting experiments utilizing the Sox9 CreERT ;Gnas R201H mouse model of FD. (A) Dams from crosses able to generate Sox9 CreERT ;Gnas (R201H)fl/+ ;Rosa26 LSL-tdTomato offspring were treated with a low dose of tamoxifen (40 mg/kg) at P6. Tamoxifen is then delivered to the pups via lactation, which allows expression of both mutant Gnas R201H and tdTomato as a lineage tracer in the subset of osteoprogenitor cells expressing Sox9 at P6. Resultant Gnas R201H ;R26 Tom mutant mice were then injected with either IgG2a or anti-RANKL antibody weekly until either P21 or P42 (3 or 6 wk of age). Femurs were collected for analysis. (B) Dams from crosses able to generate Sox9 CreERT ;Gnas (R201H)fl/+ ;Rosa26 LSL-tdTomato mice with either Rankl fl/fl or Rankl fl/+ or Rankl +/+ were genotyped to determine RANKL deletion. Pups were ear notched and genotyped at P5, the dam was treated with a low dose of tamoxifen (40 mg/kg) at P6 to deliver tamoxifen to the pups via lactation. Femurs were collected for analysis at either P21 or P42 (3 or 6 wk of age).

    Article Snippet: ELISA was performed on serum diluted 2-fold with Calibrator Diluent RD6-12 using mouse RANKL immunoassay kit (MTR00; R&D System) according to the manufacturer’s directions.

    Techniques: Expressing, Mutagenesis, Injection

    Anti-RANKL treatment decreased osteoclasts and increases trabecular bone in the Gnas R201H ;R26 Tom mouse model of fibrous dysplasia. (A) 2D and 3D images of representative micro-CT scanned femurs show the bone architecture of 3-wk-old control Gnas + ;R26 Tom (left) and Gnas R201H ;R26 Tom mutant mice (right) treated with either anti-RANKL (aRANKL) or IgG2a isotype. Arrow denotes cortical irregularity. (B) Representative images of TRAP and fast green stained femur sections from Gnas R201H ;R26 Tom mice treated with aRANKL and IgG2a. (C) Quantification of trabecular bone area (BA/TA (%) from histologic sections. (D-H) A region of interest (ROI) extending 500 μm below the growth plate from IgG2a and aRANKL treated Gnas R201H ;R26 Tom mutant mice was analyzed for number of osteoclasts per bone surface (OC.N/BS (/mm)) and osteoclast surface per bone surface (OC.S/BS (%)) at either 3 wk (D-E) or 6 wk (F-I). (D) aRANKL reduced OC.N/BS and (E) OC.S/BS in 3-wk-old Gnas R201H ;R26 Tom mice. (F) Representative images of 6-wk-old IgG2a and aRANKL treated Gnas R201H ;R26 Tom mutant mice top, with higher magnification views of inset, bottom. (G) Quantification of the total tissue area of the ROI (T.Ar (mm 2 )). (H) The number of osteoclasts per total tissue area (OC.N/T.Ar (/mm 2 )). (I) The osteoclast surface per tissue area (OC.S/T.Ar (%)). Statistical analysis was performed using non-parametric Mann–Whitney t -test, where p < .05 was considered significant.

    Journal: JBMR Plus

    Article Title: Neutralization of Receptor activator of nuclear factor-κB ligand reduces fibrosis and promotes osteoblast differentiation in a mouse model of fibrous dysplasia driven by somatic expression of Gnas R201H

    doi: 10.1093/jbmrpl/ziaf145

    Figure Lengend Snippet: Anti-RANKL treatment decreased osteoclasts and increases trabecular bone in the Gnas R201H ;R26 Tom mouse model of fibrous dysplasia. (A) 2D and 3D images of representative micro-CT scanned femurs show the bone architecture of 3-wk-old control Gnas + ;R26 Tom (left) and Gnas R201H ;R26 Tom mutant mice (right) treated with either anti-RANKL (aRANKL) or IgG2a isotype. Arrow denotes cortical irregularity. (B) Representative images of TRAP and fast green stained femur sections from Gnas R201H ;R26 Tom mice treated with aRANKL and IgG2a. (C) Quantification of trabecular bone area (BA/TA (%) from histologic sections. (D-H) A region of interest (ROI) extending 500 μm below the growth plate from IgG2a and aRANKL treated Gnas R201H ;R26 Tom mutant mice was analyzed for number of osteoclasts per bone surface (OC.N/BS (/mm)) and osteoclast surface per bone surface (OC.S/BS (%)) at either 3 wk (D-E) or 6 wk (F-I). (D) aRANKL reduced OC.N/BS and (E) OC.S/BS in 3-wk-old Gnas R201H ;R26 Tom mice. (F) Representative images of 6-wk-old IgG2a and aRANKL treated Gnas R201H ;R26 Tom mutant mice top, with higher magnification views of inset, bottom. (G) Quantification of the total tissue area of the ROI (T.Ar (mm 2 )). (H) The number of osteoclasts per total tissue area (OC.N/T.Ar (/mm 2 )). (I) The osteoclast surface per tissue area (OC.S/T.Ar (%)). Statistical analysis was performed using non-parametric Mann–Whitney t -test, where p < .05 was considered significant.

    Article Snippet: ELISA was performed on serum diluted 2-fold with Calibrator Diluent RD6-12 using mouse RANKL immunoassay kit (MTR00; R&D System) according to the manufacturer’s directions.

    Techniques: Micro-CT, Control, Mutagenesis, Staining, MANN-WHITNEY

    Anti-RANKL treatment significantly reduced fibrosis in both 3- and 6-wk-old Gnas R201H ;R26 Tom FD mouse femurs. (A-C) Masson’s trichrome stained femur sections from 3-wk-old Gnas R201H ;R26 Tom mice treated with IgG2a isotype demonstrate fibrosis (arrows), which is absent in Sox9Cre ERT ;Gnas + ;R26 TOM WT mice (C) and reduced in aRANKL treated animals. (A and B) Fibrosis in the area below the growth plate and (D) in the femoral head. Scale bar = 200 μm (A, C), 100 μm (B). (E and F) Quantification of fibrosis in the femur ROI extending 500 μm below the growth plate from IgG2a and aRANKL treated 3-wk-old Gnas R201H ;R26 Tom and Gnas + ;R26 Tom control animals. (E) Fibrosis area per tissue area (Stromal.Ar/T.Ar (%)) and (F) tissue area (T.Ar (μm 2 )) for aRANKL and IgG2a treated 3-wk-old animals. (G and H) Masson’s trichrome stained femur sections from 6-wk-old Gnas R201H ;R26 Tom mice treated with IgG2a or aRANKL. Scale bar = 200 μm (G), 100 μm (H). (I and J) Fibrosis quantified in the femur ROI extending 500 μm below the growth plate in 6-wk-old Gnas R201H ;R26 Tom mice treated with IgG2a or aRANKL and Gnas + littermates. (I) Stromal.Ar/T.Ar (%) is reduced by aRANKL without changing (J) T.Ar (μm 2 ). Statistical analysis was performed using non-parametric Mann–Whitney t -test, where p < .05 was considered significant.

    Journal: JBMR Plus

    Article Title: Neutralization of Receptor activator of nuclear factor-κB ligand reduces fibrosis and promotes osteoblast differentiation in a mouse model of fibrous dysplasia driven by somatic expression of Gnas R201H

    doi: 10.1093/jbmrpl/ziaf145

    Figure Lengend Snippet: Anti-RANKL treatment significantly reduced fibrosis in both 3- and 6-wk-old Gnas R201H ;R26 Tom FD mouse femurs. (A-C) Masson’s trichrome stained femur sections from 3-wk-old Gnas R201H ;R26 Tom mice treated with IgG2a isotype demonstrate fibrosis (arrows), which is absent in Sox9Cre ERT ;Gnas + ;R26 TOM WT mice (C) and reduced in aRANKL treated animals. (A and B) Fibrosis in the area below the growth plate and (D) in the femoral head. Scale bar = 200 μm (A, C), 100 μm (B). (E and F) Quantification of fibrosis in the femur ROI extending 500 μm below the growth plate from IgG2a and aRANKL treated 3-wk-old Gnas R201H ;R26 Tom and Gnas + ;R26 Tom control animals. (E) Fibrosis area per tissue area (Stromal.Ar/T.Ar (%)) and (F) tissue area (T.Ar (μm 2 )) for aRANKL and IgG2a treated 3-wk-old animals. (G and H) Masson’s trichrome stained femur sections from 6-wk-old Gnas R201H ;R26 Tom mice treated with IgG2a or aRANKL. Scale bar = 200 μm (G), 100 μm (H). (I and J) Fibrosis quantified in the femur ROI extending 500 μm below the growth plate in 6-wk-old Gnas R201H ;R26 Tom mice treated with IgG2a or aRANKL and Gnas + littermates. (I) Stromal.Ar/T.Ar (%) is reduced by aRANKL without changing (J) T.Ar (μm 2 ). Statistical analysis was performed using non-parametric Mann–Whitney t -test, where p < .05 was considered significant.

    Article Snippet: ELISA was performed on serum diluted 2-fold with Calibrator Diluent RD6-12 using mouse RANKL immunoassay kit (MTR00; R&D System) according to the manufacturer’s directions.

    Techniques: Staining, Control, MANN-WHITNEY

    Anti-RANKL treatment of Gnas R201H ;R26 Tom mice shifts both WT and mutant cells to a more mature osteoblast phenotype, demonstrated by increased OCN and decreased SMA expression. (A-F) Representative confocal images of femur sections from 3-wk-old Gnas R201H ;R26 Tom treated with IgG2a or aRANKL. (A) The proximal metaphyseal region of the femur from 3-wk-old IgG2a and aRANKL treated Gnas R201H ;R26 Tom mutant mice shows endogenous TdTomato (TOM + ) signal in Gnas R201H mutant cells with DAPI nuclear staining. Scale bar = 100 μm. (B and C) Cells in the ROI extending 500 μm below the growth plate were quantified to determine (B) TOM + cells per tissue area (TOM + /T.Ar (/μm 2 )) and (C) TOM + cells per trabecular bone area (TOM + /B.Ar (/μm 2 )) and TOM + cells per bone marrow area (TOM + /bone marrow area (/μm 2 )) from IgG2a and aRANKL treated Gnas R201H ;R26 Tom mice. (D-F) Images of Gnas R201H ;R26 Tom femur sections immunostained for SMA, OSX, or OCN, with DAPI nuclear stain. Endogenous tdTomato signal identifies Gnas R201H mutant cells. (G-L) Cells in the ROI extending 500 μm below the growth plate were quantified to determine (G). Percentage of TOM + Gnas R201H mutant cells that co-expressed SMA (SMA + TOM + /TOM + (%)); (H) Total SMA + cells in the ROI tissue area (SMA + /T.Ar (/μm 2 )); (I) Percentage of TOM + Gnas R201H mutant cells that co-expressed OSX (OSX + TOM + /TOM + (%)); (J) Total OSX + cells in the ROI tissue area (OSX + /T.Ar (/μm 2 )); (K) Percentage of TOM + Gnas R201H mutant cells that co-expressed OCN (OCN + TOM + /TOM + (%)); and (L) Total OCN + cells per ROI tissue area (OCN + /T.Ar (/μm 2 )). Statistical analysis was performed using non-parametric Mann–Whitney t -test, where p < .05 was considered significant.

    Journal: JBMR Plus

    Article Title: Neutralization of Receptor activator of nuclear factor-κB ligand reduces fibrosis and promotes osteoblast differentiation in a mouse model of fibrous dysplasia driven by somatic expression of Gnas R201H

    doi: 10.1093/jbmrpl/ziaf145

    Figure Lengend Snippet: Anti-RANKL treatment of Gnas R201H ;R26 Tom mice shifts both WT and mutant cells to a more mature osteoblast phenotype, demonstrated by increased OCN and decreased SMA expression. (A-F) Representative confocal images of femur sections from 3-wk-old Gnas R201H ;R26 Tom treated with IgG2a or aRANKL. (A) The proximal metaphyseal region of the femur from 3-wk-old IgG2a and aRANKL treated Gnas R201H ;R26 Tom mutant mice shows endogenous TdTomato (TOM + ) signal in Gnas R201H mutant cells with DAPI nuclear staining. Scale bar = 100 μm. (B and C) Cells in the ROI extending 500 μm below the growth plate were quantified to determine (B) TOM + cells per tissue area (TOM + /T.Ar (/μm 2 )) and (C) TOM + cells per trabecular bone area (TOM + /B.Ar (/μm 2 )) and TOM + cells per bone marrow area (TOM + /bone marrow area (/μm 2 )) from IgG2a and aRANKL treated Gnas R201H ;R26 Tom mice. (D-F) Images of Gnas R201H ;R26 Tom femur sections immunostained for SMA, OSX, or OCN, with DAPI nuclear stain. Endogenous tdTomato signal identifies Gnas R201H mutant cells. (G-L) Cells in the ROI extending 500 μm below the growth plate were quantified to determine (G). Percentage of TOM + Gnas R201H mutant cells that co-expressed SMA (SMA + TOM + /TOM + (%)); (H) Total SMA + cells in the ROI tissue area (SMA + /T.Ar (/μm 2 )); (I) Percentage of TOM + Gnas R201H mutant cells that co-expressed OSX (OSX + TOM + /TOM + (%)); (J) Total OSX + cells in the ROI tissue area (OSX + /T.Ar (/μm 2 )); (K) Percentage of TOM + Gnas R201H mutant cells that co-expressed OCN (OCN + TOM + /TOM + (%)); and (L) Total OCN + cells per ROI tissue area (OCN + /T.Ar (/μm 2 )). Statistical analysis was performed using non-parametric Mann–Whitney t -test, where p < .05 was considered significant.

    Article Snippet: ELISA was performed on serum diluted 2-fold with Calibrator Diluent RD6-12 using mouse RANKL immunoassay kit (MTR00; R&D System) according to the manufacturer’s directions.

    Techniques: Mutagenesis, Expressing, Staining, MANN-WHITNEY

    Rankl deletion in Gnas R201H ;R26 Tom mutant cells does not reduce fibrosis, alter SMA expression, nor reduce osteoclast formation in 6-wk-old mice. Formation of fibrotic lesions in Gnas R201H ;Rankl + ;R26 Tom and Gnas R201H ;Rankl Δ ;R26 Tom femurs was assessed by histology at (A-E, M-O) 3-wk and (F-L) 6-wk of age. Analysis was performed on the ROI 500 μm below the growth plate (A-L) or restricted to lesional area (M-O). (A) Representative images of TRAP stained femur sections from 3-wk-old animals counter stained with fast green. Scale bar = 200 μm. (B) Number of osteoclasts per bone surface (OC.N/BS (/mm)) and (C) osteoclast surface per bone surface (OC.S/BS (%)) within the ROI. (D) Representative images of Masson’s trichrome stained proximal metaphyseal region of the femur showed fibrosis (arrows) below the growth plate in both genotypes. Scale bar = 200 μm. (E) Fibrosis area per tissue area (Stromal.Ar/T.Ar (%)) for Gnas R201H ;Rankl Δ ;R26 Tom and Gnas R201H ;Rankl + ;R26 Tom mice. (F) Representative images of TRAP stained (pink) femur sections from 6-wk-old animals counter stained with fast green. Scale bar = 200 μm. (G) Number of osteoclasts per bone surface (OC.N/BS (/mm)), and (H) osteoclast surface per bone surface (OC.S/BS (%)) within the ROI. (I and J) Representative images of Masson’s trichrome stained proximal metaphyseal region of the femur showed fibrosis below the growth plate in both genotypes. Scale bar = 200 μm (I) and 100 μm (J). (K) Fibrosis area per tissue area (Stromal.Ar/T.Ar (%)), and (L) total tissue area (Stromal.Ar./T.AR(%)) for Gnas R201H ;Rankl Δ ;R26 Tom and Gnas R201H ;Rankl + ;R26 Tom mice, compared to Gnas + and Cre negative control littermates. (M) Representative images of SMA immunostained femur sections of 3-wk-old Gnas R201H ;Rankl + ;R26 Tom and Gnas R201H ;Rankl Δ ;R26 Tom mice. Scale bar = 50 μm. (N) Percentage of TOM + Gnas R201H mutant cells that co-expressed SMA within the lesion (SMA + TOM + /TOM + (%)). (O) Total SMA + cells per total cells (SMA + /DAPI + (%)), SMA + WT cells per total cells (SMA + TOM − /DAPI + (%)), and SMA + mutant cells per total cells (SMA + TOM + /DAPI + (%)). Statistical analysis of osteoclast parameters at both ages was performed using non-parametric Mann–Whitney t -test. Analysis of fibrosis was performed using an unpaired Student’s t -test for 3-wk-old animals and a one-way ANOVA with Tukey’s post-test for 6-wk-old animals. Analysis of SMA + cells was performed using an unpaired Student’s t -test. For all tests p < .05 was considered significant.

    Journal: JBMR Plus

    Article Title: Neutralization of Receptor activator of nuclear factor-κB ligand reduces fibrosis and promotes osteoblast differentiation in a mouse model of fibrous dysplasia driven by somatic expression of Gnas R201H

    doi: 10.1093/jbmrpl/ziaf145

    Figure Lengend Snippet: Rankl deletion in Gnas R201H ;R26 Tom mutant cells does not reduce fibrosis, alter SMA expression, nor reduce osteoclast formation in 6-wk-old mice. Formation of fibrotic lesions in Gnas R201H ;Rankl + ;R26 Tom and Gnas R201H ;Rankl Δ ;R26 Tom femurs was assessed by histology at (A-E, M-O) 3-wk and (F-L) 6-wk of age. Analysis was performed on the ROI 500 μm below the growth plate (A-L) or restricted to lesional area (M-O). (A) Representative images of TRAP stained femur sections from 3-wk-old animals counter stained with fast green. Scale bar = 200 μm. (B) Number of osteoclasts per bone surface (OC.N/BS (/mm)) and (C) osteoclast surface per bone surface (OC.S/BS (%)) within the ROI. (D) Representative images of Masson’s trichrome stained proximal metaphyseal region of the femur showed fibrosis (arrows) below the growth plate in both genotypes. Scale bar = 200 μm. (E) Fibrosis area per tissue area (Stromal.Ar/T.Ar (%)) for Gnas R201H ;Rankl Δ ;R26 Tom and Gnas R201H ;Rankl + ;R26 Tom mice. (F) Representative images of TRAP stained (pink) femur sections from 6-wk-old animals counter stained with fast green. Scale bar = 200 μm. (G) Number of osteoclasts per bone surface (OC.N/BS (/mm)), and (H) osteoclast surface per bone surface (OC.S/BS (%)) within the ROI. (I and J) Representative images of Masson’s trichrome stained proximal metaphyseal region of the femur showed fibrosis below the growth plate in both genotypes. Scale bar = 200 μm (I) and 100 μm (J). (K) Fibrosis area per tissue area (Stromal.Ar/T.Ar (%)), and (L) total tissue area (Stromal.Ar./T.AR(%)) for Gnas R201H ;Rankl Δ ;R26 Tom and Gnas R201H ;Rankl + ;R26 Tom mice, compared to Gnas + and Cre negative control littermates. (M) Representative images of SMA immunostained femur sections of 3-wk-old Gnas R201H ;Rankl + ;R26 Tom and Gnas R201H ;Rankl Δ ;R26 Tom mice. Scale bar = 50 μm. (N) Percentage of TOM + Gnas R201H mutant cells that co-expressed SMA within the lesion (SMA + TOM + /TOM + (%)). (O) Total SMA + cells per total cells (SMA + /DAPI + (%)), SMA + WT cells per total cells (SMA + TOM − /DAPI + (%)), and SMA + mutant cells per total cells (SMA + TOM + /DAPI + (%)). Statistical analysis of osteoclast parameters at both ages was performed using non-parametric Mann–Whitney t -test. Analysis of fibrosis was performed using an unpaired Student’s t -test for 3-wk-old animals and a one-way ANOVA with Tukey’s post-test for 6-wk-old animals. Analysis of SMA + cells was performed using an unpaired Student’s t -test. For all tests p < .05 was considered significant.

    Article Snippet: ELISA was performed on serum diluted 2-fold with Calibrator Diluent RD6-12 using mouse RANKL immunoassay kit (MTR00; R&D System) according to the manufacturer’s directions.

    Techniques: Mutagenesis, Expressing, Staining, Negative Control, MANN-WHITNEY